[A25-87] Andexanet alfa (acute major bleeding) – Benefit assessment according to §35a Social Code Book V
Last updated 01.10.2025
Project no.:
A25-87
Commission:
Commission awarded on 01.07.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Haematology
Adult patients treated with a direct factor Xa inhibitor (apixaban or rivaroxaban) when reversal of anticoagulation is needed due to life-threatening or uncontrollable bleeding
- Patients with intracerebral haemorrhage: hint of a lesser benefit
- All other patients in the therapeutic indication: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A25-87
| Project no. | Title | Status |
|---|---|---|
| A19-76 | Andexanet alfa (acute major bleeding) - Benefit assessment according to §35a Social Code Book V | Commission completed |